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ABSTRACT
The discovery of direct cell reprogramming and
induced pluripotent stem (iPS) cell technology
opened up new avenues for the application of non-
viral, transposon-based gene delivery systems.
The Sleeping Beauty (SB) transposon is highly
advanced for versatile genetic manipulations in
mammalian cells. We established iPS cell reprog-
ramming of mouse embryonic fibroblasts and
human foreskin fibroblasts by transposition of
OSKM (Oct4, Sox2, Klf4 and c-Myc) and OSKML
(OSKM+Lin28) expression cassettes mobilized by
the SB100X hyperactive transposase. The efficiency
of iPS cell derivation with SB transposon system
was in the range of that obtained with retroviral
vectors. Co-expression of the miRNA302/367
cluster together with OSKM significantly improved
reprogramming efficiency and accelerated the
temporal kinetics of reprogramming. The iPS cells
displayed a stable karyotype, and hallmarks of
pluripotency including expression of stem cell
markers and the ability to differentiate into embryoid
bodies in vitro. We demonstrate Cre recombinase-
mediated exchange allowing simultaneous removal
of the reprogramming cassette and targeted
knock-in of an expression cassette of interest into
the transposon-tagged locus in mouse iPS cells.
This strategy would allow correction of a genetic
defect by site-specific insertion of a therapeutic
gene construct into ‘safe harbor’ sites in the
genomes of autologous, patient-derived iPS cells.
INTRODUCTION
As a result of their plasticity and self-renewal capacity,
human embryonic stem (ES) cells represent valuable
tools for research and therapy, including tissue replace-
ment following injuries or disease (1). However, there
are several drawbacks involved with application of
human ES cells, such as ethical issues concerning deriv-
ation of these cells from human embryos, and biological
issues such as immune rejection once transplanted into
incompatible recipients. To circumvent these problems,
several methods have been proposed for the derivation
of pluripotent cells from somatic cells including nuclear
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transplantation, cellular fusion and direct reprogramming
by expression of pluripotency-related transcription
factors. Direct reprogramming of differentiated somatic
cells by gene transfer of a small number of deﬁned tran-
scription factors, namely Oct4, Sox2, Klf4 and c-Myc
(OSKM), has been shown to yield cells that are highly
similar to ES cells in gene expression proﬁles, morph-
ology, pluripotency and in vitro differentiation (2). In
the mouse system, these induced pluripotent stem (iPS)
cells have the ability to generate germline chimeras and
mice fully derived from iPS cells following tetraploid
complementation [reviewed in (3)]. In contrast to ES
cells, iPS cells can be obtained from autologous, adult
somatic cells, thereby obviating the need for prolonged
immunosuppressive therapy in the context of cell trans-
plantation. iPS cells can be genetically modiﬁed and can
be coaxed to differentiate into endodermal, mesodermal
and ectodermal cell types. Thus, the iPS cell technology
offers a versatile and promising means for a variety of
applications including modeling of monogenic and
complex, multigenic traits and diseases, screens for
drugs, cell differentiation, toxicology and autologous
cell therapy (4–13). In one landmark study, iPS cells
derived from ﬁbroblasts of sickle cell anemia mice were
genetically corrected by replacing the mutant b-globin
allele with a wild-type allele by means of homologous
recombination. This provided a source of iPS cells
able to differentiate into disease-free hematopoietic pre-
cursors that cured the afﬂicted mice following transplant-
ation (6).
The most widely applied methods for iPS cell
reprogramming rely on the introduction of different com-
binations of transcription factors in the form of DNA,
mRNA or protein into somatic cells. The early studies
applied retroviral vectors for stable genomic insertion of
the reprogramming genes (2,14,15). Oncogenicity of the
factors used in reprogramming and the potential for
insertional mutagenesis caused by integrating retroviral
gene transfer vectors limit the value of the resulting iPS
cells for clinical applications (16), and it is believed that
avoiding multiple, permanent retroviral insertions will be
a strict requirement for clinical translation of iPS cells.
These concerns lead to the development of alternative
approaches to reprogramming, including elimination of
chromosomally integrated reprogramming genes from
iPS cells by using Cre/lox or Flp technology (17–19), use
of non-integrating gene transfer systems to deliver the
reprogramming genes (20–22) and use of small-molecule
chemicals in combination with genetic factors (23). For
example, it was demonstrated that transient expression
of the four key reprogramming factors using replication-
incompetent adenoviral and Sendai viral vectors vectors
can give rise to iPS cell lines (21,24,25). Similar, proof-
of-concept for the applicability of Epstein-Barr Virus-
derived oriP/EBNA1 episomal vector systems and
transfection of plasmid constructs for the generation of
iPS cells was recently obtained (20,22,26). Non-integrating
reprogramming systems also include minicircle vectors
(27), delivery of synthetic mRNAs encoding the
reprogramming factors (28), transfection of miRNAs
(29) and recombinant protein transduction (30,31).
These important reports provide proof-of-concept
for the generation of iPS cells without transgene
integration, but at a >100-fold lower efﬁciency. Gradual
reduction in reprogramming factor expression over a
few days as the cells divide likely contributes to the
low efﬁciency of non-integrating gene delivery sys-
tems, suggesting that prolonged (>10 days) expression
of reprogramming factors is required for efﬁcient
reprogramming.
DNA transposons are discrete pieces of DNA with the
ability to change their positions within the genome via a
cut-and-paste mechanism called transposition. These
mobile genetic elements can be harnessed as gene delivery
vector systems that can be used as tools for versatile appli-
cations [for review, see (32)]. The paradigmatic use of any
transposon-based vector system relies on transient expres-
sion of a transposase enzyme that enables genomic insertion
of a gene of interest (GOI) ﬂanked by terminal inverted
repeats (TIRs) of the transposon (Figure 1A) [for review,
see (32)]. In contrast to viral vectors, transposon vectors can
be maintained and propagated as plasmid DNA, thereby
providing simplicity and safety to the user. Because trans-
position proceeds through a cut-and-paste mechanism that
only involves DNA, transposon vectors are not prone to
incorporating mutations by reverse transcription (that are
generated in retroviral stocks at reasonable frequencies),
and can tolerate larger and more complex transgenes (33).
piggyBac (PB) transposons have been shown to be applic-
able for iPS cell generation and, through repeated expres-
sion of the transposase in reprogrammed cells, the
chromosomally integrated vector can be excised from the
genome, thereby resulting in genetically ‘clean’ iPS cells
(34,35). However, there are applications where the use of
the other transposon systems could prove advantageous.
The Sleeping Beauty (SB) transposon system (36) has
several advantages over other transposon systems, including
PB. First, transposition efﬁciency was greatly enhanced by
the novel hyperactive SB100X transposase (37) that yields
stable gene transfer efﬁciencies higher than that of PB (38)
and comparable to those of integrating viral vectors,
enabling highly efﬁcient transgene integration and expres-
sion. Second, SB-based vectors are likely superior in safety
because (i) SB shows a random genomic insertion proﬁle
without overt preference for integrating into genes and
their transcriptional regulatory regions, whereas PB shows
preferential integration into transcription units (38,39) and
(ii) in comparison to PB transposons (40) the TIRs of SB
vectors have negligible enhancer/promoter activity (41,42).
Finally, as opposed to PB (43), there are no SB-related
sequences in mammalian genomes, thereby precluding po-
tential cross-mobilization between endogenous and exogen-
ously introduced transposons.
We and others postulate that the ultimate therapeutic
potential of iPS cells will be greatly enhanced by safe
methods of genome engineering allowing targeted intro-
duction of therapeutic gene cassettes (44). Here, we show
iPS reprogramming of mouse embryonic ﬁbroblasts
(MEFs) and human foreskin ﬁbroblasts (HFFs) by
stable transposition of polycistronic OSKM and
OSKML (also containing Lin28) expression cassettes
mobilized by the SB100X transposase. The iPS cells
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show hallmarks of pluripotency, such as expression of
stem cell markers and the ability to differentiate into
embryoid bodies (EBs) in vitro. We demonstrate Cre
recombinase-mediated exchange allowing simultaneous
removal of the reprogramming cassette and targeted
knock-in of an expression cassette of interest into the
transposon insertion locus. We propose this novel
approach of generating iPS cells as a viable and efﬁcient
alternative to other related methods.
MATERIALS AND METHODS
SB transposon-based reprogramming vectors
The CAG.OSKM-putk and CAG.OSKML-putk
sequences containing the cDNAs of the open reading
frames of the four Yamanaka factors (mouse Oct4,
Sox2, Klf4 and Myc) with or without Lin28 were
removed from PB vectors as described earlier (35) by
NheI and NotI and cloned into the SpeI and NotI sites
Figure 1. SB transposon-based vector system for iPS cell reprogramming. (A) The transposon is used as a bi-component vector system for delivering
transgenes that are maintained in plasmids. One component contains a GOI between the transposon TIRs (black arrows), the other component is the
transposase protein (pink spheres). The transposon is excised from the donor plasmid and is integrated at a chromosomal site by the transposase.
(B) Schematic representation of SB transposon-based reprogramming vectors. Individual genes in four- and ﬁve-factor cassettes were linked by 2A
self-cleaving peptide sequences and expressed from the CAG promoter. The miRNA302/367 cluster located in an intron is inserted in the
reprogramming cassette. The pluripotency-reporting vector contains an EOS(3+)-mCherry pluripotency reporting cassette that consists of an ETn
LTR coupled with a trimer of the Oct4 enhancer motif EOS(3+) driving the expression of mCherry. Black arrows represent SB transposon TIRs;
bpA, bovine growth hormone polyadenylation signal; putk, PGK promoter-driven putk expression cassette. (C) Transposition of the four- and
ﬁve-factor reprogramming transposons (pT2-OSKM and pT2-OSKML) in HeLa cells. In total, 2.5  105 cells were transfected with 500 ng
of transposon-based reprogramming donor plasmids and 50 ng of transposase expression plasmids, placed under puromycin selection, and the
resultant antibiotic-resistant colonies were stained.
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of the pT2HB SB vector. Both resulting constructs con-
tained a CAG-promoter driven reprogramming cassette
[the reprogramming factors were combined into a single
open reading frame separated by sequences encoding
viral 2A peptides (45)], and a puDtk cassette, ﬂanked by
SB inverted terminal repeats. The promoter-enhancer
fragment EOS(3+) was cut out of the PL-SIN-
EOS-C(3+)-EiP vector (46) with NcoI/MfeI and the
fragment ends were blunted with Klenow polymerase.
The EOS(3+) fragment was then cloned into the Klenow
polymerase-treated AgeI site of pCAGGS-mCherry-C1.
The EOS(3+)-mCherry fragment was then cut out
from the pEOS(3+)-mCherry-C1 plasmid with MluI/
BamHI, and cloned into the MluI/BglII sites of the
pT2-CAG.OSKM-putk and pT2-CAG.OSKML-putk
plasmids. A DNA fragment containing the
miRNA302/367 cluster was ampliﬁed from mouse
genome by polymerase chain reaction (PCR) as described
earlier (29). The ampliﬁed fragment was directly inserted
between the reprogramming cassette and polyA
sequence in the SB-based reprogramming vector pT2-
OSKM.
Cell culture
HeLa cells were plated onto a six-well plate at a density of
2.5  105 cells per well 24 h prior to transfection. On the
following day, the cells were co-transfected with 500 ng of
transposon donor plasmids and 50 ng transposase expres-
sion plasmids, using FuGENE transfection reagent
(Roche). To measure the transposition activity of these
vectors in a colony-forming assay, the transfected cells
were replated into 10-cm tissue culture dishes in 1:10
ratio 48 h post-transfection, and subjected to puromycin
antibiotic selection.
Mouse OG2 MEFs were derived from OG2 mice (47)
and cultured in mouse MEF medium: low glucose
Dulbecco’s Modiﬁed Eagle’s medium (DMEM) without
glutamine containing 10% fetal bovine serum (FBS)
supplemented with 2mM L-glutamine, 1 nonessential
amino acids, 0.1mM 2-mercaptoethanol and 100 mg/ml
primocin (InvivoGen). CF1-MEFs were grown in
mouse MEF medium containing DMEM supplemented
with 10% FBS, 1 nonessential amino acids, 0.1mM
2-mercaptoethanol and 100 mg/ml primocin. HFFs-1
were purchased from ATCC. Cells were cultured in
DMEM (Invitrogen) supplemented with 10% FBS
(Invitrogen) at 37C under humidiﬁed atmosphere of air/
CO2 (19:1).
Mouse iPS cells were cultured in mouse iPS medium
containing knockout DMEM with 15% FBS, 2mM L-glu-
tamine, 1nonessential amino acids, 0.1mM 2-mercap-
toethanol, 25 mg/ml L-ascorbic acid, 100 mg/ml primocin
and puriﬁed recombinant leukemia inhibitory factor
(LIF). Mouse iPS clones were maintained either on
mytomicin-c-arrested feeders (CF1-MEFs) or on geltrex
(1:200 dilution in F-12 DMEM). Human iPS cells were
maintained on mitomycin C-treated MEF (CF-1) feeder
cell layers (Millipore) in ESC medium: 80% KO-DMEM
(Invitrogen) supplemented with 15% Serum Replacement,
1% nonessential amino acids (Invitrogen), 1mM
L-glutamine (Invitrogen), 0.1mM beta-mercaptoethanol
(Invitrogen) and 4 ng/ml human ﬁbroblast growth
factor (Invitrogen). Established iPS cells were passaged
1:2 every 72 h.
Reprogramming of MEFs using SB-based vectors
Twenty-four hours prior to electroporation OG2 cells
were plated onto geltrex-coated six-well plates (2.5  105
cells per well). The next day cells were electroporated with
the Neon
TM
transfection system (Invitrogen) according to
the manufacturer’s instructions. In each electroporation
reaction, 5  105 cells were electroporated with 550 ng
DNA [100, 250 or 500 ng of transposon vectors and
50 ng of CMV-SB100X vector expressing the enhanced
SB100X transposase (37)]. Electroporation reactions
were ﬁlled up to 550 ng DNA with pFV4a(CAT)
plasmids. The conditions used for electroporation were
1350V pulse voltage, 30ms pulse width and one pulse.
After the electroporation, each reaction was plated onto
a geltrex-coated well of a six-well plate containing iPS
medium. For the ﬁrst 10 days medium was changed
daily. Valproic acid (VPA) (Ergrnyl; Sanoﬁ Aventis) was
added to the iPS medium at 2mM from day 2 until day 9
post-electroporation. Colonies were picked over days
14–20, trypsinized and plated onto feeders or
geltrex-coated wells of a 24-well plate.
Generation of human iPS cells by SB transposons
HFF-1 cells (4  105 cells per well) were transfected by
Nucleofection (Lonza) according to the manufacturer’s
instructions. In each transfection, 2 mg of transposon
plasmid (pT2-OSKM or pT2-OSKML) and 0.2 mg of the
CMV-SB100X vector were used. After transfection, the
cells were plated onto Matrigel-coated (hES cell-qualiﬁed
Matrix, BD Biosciences) six-well plates and were grown in
MEF-conditioned ES medium. The medium was refreshed
every day. Newly formed hiPS colonies were picked and
transferred to Matrigel-coated 24-well plates, and
expanded 4–6 days in MEF-conditioned ES medium.
Cells were dissociated with trypsinization, plated onto
feeder cells and cultivated in ES medium.
Recombinase-mediated cassette exchange
Mouse iPS cells (106) were resuspended in pre-warmed
PBS after trypsinization, and centrifuged at 250 g for
5min. The supernatant was aspirated and the
recombination-mediated cassette exchange (RMCE)/
CAG-mCherry plasmid was added to the cells, which
were resuspended in Buffer R with gentle pipetting in a
total volume of 110 ml. Cells were transfected with the
Neon
TM
transfection system with the following settings:
pulse voltage 1350V, pulse width 30ms and single pulse.
The transfected cells were transferred into pre-warmed
mouse iPS medium in a 10-cm feeder-coated dish. The
cells were fed with fresh mouse iPS medium the next day
and cultured for additional 2 days before FIAU (Moravek
Biochemicals) selection (200 ng/ml). After selection for
2weeks, surviving colonies that expressed mCherry were
picked and expanded in 24-well plates.
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In vitro differentiation assays
Undifferentiated, collagenase IV dissociated hiPSC were
transferred to poly-2 hydroxyethyl-methacrylate
(polyHEMA, Sigma-Aldrich) coated six-well plates.
Cells were kept in suspension to generate EBs in EB
medium consisting of 77.8% KO DMEM (Invitrogen),
20% ES tested FBS (Invitrogen), 1% nonessential amino
acids (Invitrogen), 0.1mM beta-mercaptoethanol
(Invitrogen) and 1mM L-glutamine (Invitrogen). EB
medium was refreshed every day. Six days later EBs were
placed onto gelatin-coated plates, the attached cells further
differentiating spontaneously in DMEM supplemented
with 10% ES tested FBS. Immunohistochemistry for or
mRNA isolation was performed at the indicated times.
Immunohistochemistry and confocal microscopy
Mouse iPS cells were grown on inactivated MEFs in
12-well plates containing gelatinized (0.1% gelatine)
glass cover slip inserts. To detect the expression of Sox2
and SSEA-1, immunostaining was performed with the
ASC mES/iPS cell characterization kit (Applied
StemCell) according to the manufacturer’s instructions.
To detect the expression of the Nanog, rabbit polyclonal
anti-Nanog primary antibody (1:300) was used in conjunc-
tion with the ASC mES/iPS cell characterization
kit. CF1-MEF cells were used as a negative and mouse
E14 Tg2a ES cells as a positive control for the
immunostainings.
Human iPS cells seeded onto eight-well Nunc Lab-Tek
II Chambered Coverglass (Nalge Nunc International)
were ﬁxed with 4% paraformaldehyde (PFA) in
Dulbecco’s modiﬁed PBS (DPBS) for 30min at room tem-
perature. After DPBS washing steps, the samples were
blocked for 1 h in DPBS containing 2mg/ml bovine
serum albumin, 1% ﬁsh gelatin, 5% goat serum and
0.1% Triton-X 100. Samples were then incubated for 1 h
with primary antibodies. After extensive washes with
DPBS, the corresponding ﬂuorescently labeled secondary
antibodies and DAPI (Invitrogen) for nuclear staining
were added for another hour. Primary antibodies: anti-
Oct4 (Santa Cruz Biotechnology), anti-Nanog (R&D
Systems Inc), anti-SSEA4 (R&D Systems Inc), anti-
podocalyxin (R&D Systems Inc), anti-a-fetoprotein
(Sigma-Aldrich), anti-a-smooth muscle actin (Sigma-
Aldrich) and anti-b-tubulin III (R&D Systems Inc).
Alexa 488-labeled anti-mouse and Cy3-labeled anti-goat
secondary antibodies were obtained from Jackson
ImmunoResearch Laboratories. Samples were examined
on an Olympus FV500-IX confocal laser scanning
microscope.
Alkaline phosphatase staining
Cells were ﬁxed with 4% formaldehyde in PBS for 30min.
Cells were then washed with PBS (3  5min) and stained
with BM Purple or BCIP

/NBT Liquid Substrate System
(Sigma-Aldrich) for an hour at room temperature.
CF1-MEF cells were used as a negative and mouse E14
Tg2a cells as a positive control.
Flow cytometry
Cells were washed once in PBS containing 0.5% bovine
serum albumin and incubated for 30min with different
directly labeled anti-human antibodies: CD44-FITC,
CD73-PE, CD90-PE (BD Pharmingen), PODXL-PE and
SSEA4-APC (R&D Systems). In all samples, an anti-
mouse Sca-1 (Ly-6A/E) (FITC or PE, BD Pharmingen)
antibody was employed, for gating out the positively
labeled mouse feeder cells. Samples were analyzed by a
FACS-Calibur ﬂow cytometer (Becton Dickinson
Immunocytometry Systems) equipped with a 488-nm
argon laser and a 635-nm red diode laser with CellQuest
acquisition software (BDIS). iPS clones were obtained by
cell sorting for SSEA4 positive cells using an Aria High
Speed Cell Sorter (Beckton-Dickinson).
RT-PCR analysis
Embryoid bodies and human iPS cells were seperated
from differentiated cells and from feeder cells using the
Anti-TRA-1-60 MicroBead Kit (Miltenyi Biotec), and
RNAs were extracted by using the RNAqueous-4PCR
Kit (Ambion) following the instructions of the manufac-
turers. Total RNA (0.1 mg) was used for reverse transcrip-
tion by using random hexamer primers from the Promega
Reverse Transcription System Kit or with the High
Capacity RNA-to-cDNA kit (Applied Biosystems).
Quantitative RT-PCR was carried out using Taqman
Gene Expression Master Mix (Applied Biosystems) and
pre-designed TaqMan Gene Expression Assays (Applied
Biosystems) on the StepOne Plus Real-Time PCR System
(Applied Biosystems), according to the manufacturer’s in-
structions and by using Power SYBR

Green PCRMaster
Mix (Applied Biosystems) on the ABI7900HT sequence
detector (Applied Biosystems). All data were normalized
to GAPDH expression.
Transcriptome proﬁling
For microarray analysis, quality-controlled DNA-free
RNA samples to be hybridized on Illumina human-12
V4 expression BeadChips were processed using a linear
ampliﬁcation kit (Ambion) to generate biotin-labeled
cRNA through 14 h of in vitro transcription. Puriﬁed
cRNA was quality-checked on a 2100 Bioanalyzer
(Agilent), and hybridized as recommended and using ma-
terials/reagents provided by the chip manufacturer.
Karyotyping
iPS cells were arrested with KaryoMAX Colcemid
Solution (Invitrogen) for 30min and harvested using
trypsin-EDTA. Hypotonization was performed with
prewarmed, 75mMKCl. A 3:1 mixture of methanol and
acetic acid was used for cell ﬁxation. Slides were dropped
and aged for 3 days. Samples were analyzed following
trypsin banding and Giemsa staining on a Nikon Eclipse
E600 microscope equipped with a COHU 4912 CCD
camera. Karyotyping was performed using Applied
Imaging MacKtype v5.6 software.
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Transposon copy number analysis
Transposon copy numbers were determined by
splinkerette PCR. Genomic DNA from the iPS clones
was isolated with the GeneJET
TM
Genomic DNA
Puriﬁcation Kit according to the manufacturer’s instruc-
tions, and 1 mg samples were digested with DpnII for 4 h.
The samples were puriﬁed with the QIAquick PCR
Puriﬁcation Kit (Qiagen) according to the manufacturer’s
instructions, and ligated (150 ng) to MboI splinkerette
adapters (25 pmol) in 20 ml reactions. Five microliters of
the ligation reaction were used for the ﬁrst PCR with
primers Linker primer and T-Bal Rev with a cycle of
94C for 3min, followed by 15 cycles of 94C for 30 s,
70C for 30 s and 72C for 30 s; 5 cycles of 94C for
30 s, 63C for 30 s and 72C for 2 s with an increase of a
2 s per cycle; 5 cycles of 94C for 30 s, 62C for 30 s and
72C for 12 s with an increase of 2 s per cycle; 5 cycles of
94C for 30 s, 61C for 30 s and 72C for 22 s with an
increase of 2 s per cycle and 5 cycles of 94C for 30 s,
60C for 30 s and 72C for 30 s. Nested PCR was done
with primers Nested and T-Bal with a cycle of 3min at
94C followed by 10 cycles of 94C for 30 s, 65C for 30 s
and 72C for 30 s and 20 cycles of 94C for 30 s, 58C for
30 s and 72C for 30 s. The ﬁnal elongation was performed
for 5min at 72C.
Bisulﬁte sequencing
Bisulﬁte reactions were performed using the kit according
to the manufacturer’s instructions (Qiagen). Five micro-
liter of bisulﬁte-treated genomic DNA was used in a
standard PCR protocol to amplify the Oct4 and Nanog
promoter regions in mouse and human iPS cells and their
parental ﬁbroblasts (OG2 cells and HFF). PCR products
were cloned into pGEM-T vectors (Promega) and
sequenced using the M13 forward primer. Primers used
to amplify the Oct4 promoter region were described
earlier (2).
Array-CGH analysis
Array-CGH was performed using the Agilent Mouse
Genome Microarray Kit 244 k (Agilent Technologies,
Santa Clara, CA, USA) high-resolution 60-mer
oligonucleotide-based microarray with median overall
probe spacing of 10.9 kb. Labeling and hybridization
of genomic DNA was performed according to the
protocol provided by Agilent. Brieﬂy, 0.75 mg of test
DNA was labeled by random priming using the Agilent
Genomic DNA Labeling Kit Plus, test DNA (mouse
pre-RMCE and post-RMCE iPS cells) with Cy3-dUTP
and reference DNA (mouse OG2 ﬁbroblast) with
Cy5-dUTP. Labeled products were puriﬁed by Amicon
Ultra 30 k ﬁlters (Millipore, Billerica, MA, USA),
combined and then mixed with mouse Cot-1 DNA
(50mg), Agilent 10 Blocking Agent and Agilent 2
Hybridization Buffer. This solution was hybridized to
Agilent’s 4 180 k Mouse Genome CGH microarray at
65C with 20 rpm rotation for 24 h. Washing steps were
performed according to the Agilent protocol. Microarray
slides were scanned immediately using an Agilent
microarray scanner at a resolution of 2 mm. For image
analysis, default CGH settings of Feature Extraction
Software (Agilent Technologies, Waldbronn, Germany)
were applied. Output ﬁles from Feature Extraction were
subsequently imported into Agilent’s CGH data analysis
software, DNA-Workbench. The Aberration Algorithm
ADM2 was applied and Aberration Filters were set to
threshold 15.0, at least four probes with mean log2 ratio
of 0.5.
Histological analysis of EBs
Twenty-day-old human EBs were used for histological
analysis, as previously described (48). EBs were brieﬂy
centrifuged at 800 rpm to remove the medium and subse-
quently coagulated by mixing with bovine plasma and
thrombin (Sigma-Aldrich) at a ratio of 2:1. Formation
of the clot containing 30–40 EBs was followed by over-
night ﬁxation in 4% PFA. EBs were brieﬂy rinsed in dis-
tilled water to remove PFA, dehydrated through a graded
series of alcohol solutions (70–100%) and xylene, and
embedded in parafﬁn for sectioning. Hematoxylin and
eosin staining was performed on microscope slide-
mounted, 0.3mm sections by standard procedures.
Images were obtained using a Zeiss AxioVision Rel. 4.8
imaging system and 40/0.75 objective magniﬁcation.
RESULTS
Generation of mouse iPS cells by SB transposition
To explore the utility of the SB transposon as a
reprogramming tool for the delivery of reprogramming
genes into cells, two reprogramming vectors were con-
structed, containing either an OSKM or an OSKML (con-
taining Lin28 in addition to the OSKM factors) expression
cassette driven by the constitutively active CAG promoter
(Figure 1B) (35). The reprogramming factors were
combined into a single reading frame with the help of
2A self-cleaving peptide sequences. In addition, a putk
cassette allowing both positive (resistance to puromycin)
and negative (sensitivity to gancyclovir) was also included
in the SB transposon vectors (Figure 1B). Both SB
reprogramming vectors were transpositionally active in
human HeLa cells (Figure 1C). Next, we investigated
cellular reprogramming in MEFs, by taking advantage
of the OG2 transgenic line that expresses a GFP transgene
driven by the Oct4 promoter (49). Thus, MEFs isolated
from OG2 embryos do not express GFP, but iPS cells
derived from the MEFs do (due to activation of the
Oct4 promoter in pluripotent stem cells), which can be
detected by ﬂuorescent microscopy. The advantage of
these genetically marked cells, therefore, lies in the possi-
bility to monitor the reprogramming process.
About 5  105 early passage (P3) OG2-MEFs were
electroporated with 100, 250 and 500 ng of transposon
plasmids containing the reprogramming cassettes
together with 50 ng of the SB100X transposase expression
plasmid, and the cells were grown in the presence or
absence of VPA that was shown to enhance the
reprogramming process (23,50). In the presence of VPA,
the ﬁrst iPS-like colonies became visible between day 7
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and 10, and green ﬂuorescence could be observed several
days later (around day 14, depending on the construct and
the transfected plasmid amounts) (Figure 2). In the
absence of VPA, colonies with a pre-iPS-like morphology
started to form on day 3 post-electroporation, with GFP
expression evident already at day 7.
As alkaline phosphatase (AP) is a stem cell membrane
marker, and elevated expression of this enzyme is
associated with an undifferentiated pluripotent stem cell
state, the iPS cell colonies were stained for AP expression
(Figure 2A), and counted to derive iPS reprogramming
efﬁciencies. The highest numbers of AP-positive colonies
Figure 2. Characterization of mouse iPS clones generated with SB-based reprogramming vectors. (A) AP staining of iPS cell clones 24 days
post-electroporation (top) and mouse ES cells (bottom). (B) iPS colony forming efﬁciencies of the pT2-OSKM and pT2-OSKML reprogramming
vectors. A total of 100, 250 and 500 ng of transposon reprogramming vectors were electroporated together with 50 ng of the transposase expression
plasmid pCSB100XNpA. At the 250 ng transposon dose, transfected cells were incubated in the presence or absence of VPA. (C) Immunostaining of
Nanog, SSEA-1 and Sox2 in iPS cells at day 24 post-electroporation. Note that in addition to endogenously expressed Sox2, the antibody could have
also reacted with exogenous Sox2 expressed from the reprogramming cassette. In addition, iPS cell clones generated from transgenic OG2-MEF cells
express GFP from the endogenous Oct4-GFP locus. BF, bright ﬁeld. (D) Transposon copy numbers in mouse iPS cells. iPS cell clones were generated
by electroporation of 5  105 OG2-MEF cells with 100 ng of reprogramming transposon vectors and 50 ng of transposase expression vectors. Copy
numbers of integrated OSKM and OSKML transposons were determined by splinkerette PCR; asterisks mark iPS cell clones with single-copy
integrated transposons.
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were obtained with electroporation of 250 ng of trans-
poson and 50 ng of transposase plasmids (Figure 2B).
Altogether, the OSKML SB vector was more efﬁcient in
iPS cell colony generation than the OSKM vector, and the
increase in the reprogramming efﬁciency correlated with
the increase in the amount of the reprogramming plasmids
that were electroporated into the cells (Figure 2B).
Consistent with earlier results showing a lack of enhance-
ment of reprogramming by VPA in human and mouse
ﬁbroblasts following PB transposon-mediated gene
transfer (35), colony formation was altogether higher in
the absence of VPA (Figure 2B), but these iPS cell colonies
displayed different morphology than those that grew in
the presence of VPA. Generally, they were much larger
than the VPA-treated colonies and more ﬂat, lacking the
typical spherical, clump-like morphology of murine ES
cells. In addition, these colonies were positive for AP
expression, but did not express GFP ubiquitously, but
rather in smaller patches that seemed to be concentrated
at areas of colonies showing increased cell division.
Nevertheless, if these colonies were picked and passaged
on feeder cells, their morphology changed to a typical
ES-like state, and they started to express GFP ubiqui-
tously (Supplementary Figure S1).
To investigate the pluripotency of these iPS cells,
colonies with ES-like morphology were picked (mechan-
ical picking followed by trypsinization of colonies),
plated onto mouse feeder cells and subsequently used for
AP- and immunostaining. In addition to the activation of
the endogenous Oct4 promoter, which was conﬁrmed by
green ﬂuorescence of the reprogrammed cells, the
iPS colonies also expressed endogenous pluripotency
markers, including SSEA-1, Nanog and Sox2
(Figure 2C). The generated iPS colonies resembled in all
instances mouse ES cell colonies that were used as a
positive control for the immuno- and AP stainings,
except for the expression of GFP that was speciﬁc for
the OG2-transgenic cells (Figure 2C).
We investigated copy numbers of the integrated trans-
posons by splinkerette-PCR. The iPS cell clones had trans-
poson insertions in the range of 1–6 copies per clone
(Figure 2D). Copy number was in general higher in
OSKM-generated cells than in OSKML-generated cells
(Figure 2D), consistent with either a higher transposition
efﬁciency of the shorter OSKM transposon, or with higher
gene dosage of the OSKM cassette required for iPS
reprogramming. Importantly, 10% of the colonies had
a single-copy integration (Figure 2D), allowing subse-
quent engineering of the insertion locus.
Cre recombinase-mediated exchange of the reprogramming
cassette in mouse iPS cells
Differentiation of iPS cells into various cell lineages
requires removal of the reprogramming genes. However,
because correction of genetic deﬁciencies may necessitate
stable genomic insertion of therapeutic transgene cassettes
in patient-derived cells, we reasoned that these two steps
(removal of the reprogramming cassette and addition of a
new expression cassette) could be achieved simultaneously
by RMCE (Figure 3A). We previously developed a
strategy for Cre recombinase-mediated RMCE in trans-
genic pig ﬁbroblasts (51). In an analogous fashion, we
ﬂanked the OSKM cassette in the SB transposon vector
by heterospeciﬁc loxP and loxP257 recombination sites
(Figure 3A). This vector was used to generate mouse iPS
cells from OG2 ﬁbroblasts, and a single-copy iPS cell line
was employed for RMCE. The iPS cells were
electroporated with two plasmids, one containing an
mCherry marker cassette ﬂanked by the loxP and
loxP257 sites and another transiently expressing Cre
recombinase. RMCE yielded cells at an efﬁciency of
0.01% that were resistant to FIAU due to loss of the
TK marker in the reprogramming construct and that were
red ﬂuorescent due to genomic insertion of the mCherry
expression cassette (Figure 3B). Genotyping of three indi-
vidual iPS cell colonies with PCR primer pairs speciﬁc
either to the reprogramming cassette or to transposon
vector and mCherry sequences (Figure 3A) conﬁrmed
loss of the reprogramming cassette and gain of the
mCherry cassette at the transposon-tagged genomic locus
(Figure 3C).
Similar to their parental cells, the exchanged,
reprogramming factor free iPS cells had an ES cell-like
morphology, and expressed GFP from the Oct4
promoter (Figure 3B), suggesting that they retained
pluripotency. By means of high resolution array-CGH
no chromosomal copy number alterations, deletions or
duplications were identiﬁed in pre- or post-RMCE
mouse iPS cells (Figure 3D). To investigate the DNA
methylation status of the Nanog promoter, bisulﬁte
sequencing on genomic DNAs isolated from parental
and exchanged iPS cells and from OG2 ﬁbroblasts was
performed. As shown in Figure 3E, the promoter region
of Nanog was demethylated in mouse iPS cells and
methylated in OG2 ﬁbroblasts, indicating that the epigen-
etic state of the Nanog gene was successfully reprog-
rammed from a transcriptionally repressed to an active
state, and that this reprogrammed state was maintained
in reprogramming factor-free iPS cells. To further charac-
terize reprogramming factor-free mouse iPS cells on a mo-
lecular level, we determined the expression of mouse ES
cell-speciﬁc genes. As shown in Figure 3F, these genes
were highly expressed in parental as well as exchanged,
reprogramming factor-free mouse iPS cells, as compared
with OG2 ﬁbroblasts.
The exchanged iPS cells formed EBs in vitro, and
differentiated into the three germ layer lineages indicated
by immunocytochemical stainings for the lineage markers
a-SMA, b3-tubulin and Sox17 (Figure 4A). Consistent
with the loss of pluripotency (and transcriptional deacti-
vation of the Oct4 promoter) during in vitro differenti-
ation, the GFP signal disappeared in EBs derived from
the exchanged iPS cells during the ﬁrst week of culture
(Figure 4A). Mouse iPS cell clones were subjected to
gene expression (mRNA) analysis, and found to display
upregulated expression of multiple, speciﬁc differentiation
markers representing the three germ layers (Figure 4B).
Taken together, RMCE allows removal of reprogramming
genes and simultaneous knock-in of transgenes of interest
at transposon-tagged loci in iPS cells that retain
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Figure 3. Cre recombinase-mediated cassette exchange in mouse iPS cells. (A) Schematic representation of RMCE. The OSKML expression cassette
plus positive/negative selection cassette is ﬂanked by heterospeciﬁc loxP sites alowing simultaneous removal of the reprogramming cassette from a
genomically integrated, transposon-tagged locus and site-speciﬁc integration of an exogenously supplied transgene of interest also ﬂanked by com-
patible loxP sites. RMCE is dependent on transient expression of Cre recombinase. (B) RMCE in mouse iPS cells. The OSKML factors plus
selection genes were exchanged with mCherry in a single-copy mouse iPS clone following FIAU (200 nM) selection for 2 weeks. (C) Genomic PCR
analysis of the exchanged iPS clone with primers shown in A, designed to detect the reprogramming cassette (top gel) and mCherry within a
transposon vector (bottom gel). Lanes: (1) parental iPS clone, (2–5) iPS clones after RMCE and selection in FIAU, (6) OG-2 MEFs (negative
control). The PCR products in lanes 2, 3 and 4 indicate that the reprogramming cassette was successfully exchanged with mCherry. (D) The genomic
proﬁles of pre-RMCE (brown) and post-RMCE (red) mouse iPS cells by means of array-CGH (244 k, Agilent). Cy3/Cy5 ratios of each individual
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pluripotency in the absence of exogenous pluripotency
factors.
SB-based pluripotency-reporting reprogramming vectors
Use of genetically engineered cells that can report
reprogramming into a pluripotent state, such as the
OG2 MEFs, is advantageous, since they can facilitate
fast and easy identiﬁcation of reprogrammed cells.
However, the beneﬁts of such cells are not available for
the generation of autologous, patient-derived human iPS
cells. To circumvent this limitation, we incorporated a
pluripotency reporter cassette into the SB-based
reprogramming vectors (Figure 1B). The pluripotency
reporter cassette consisted of mCherry expressed from
the strong LTR promoter of an Early Transposon (ETn)
that is highly transcribed in ES cells (52) coupled with a
trimer of Oct4 binding site. This promoter-enhancer com-
bination is not active in differentiated cells, and was there-
fore speciﬁcally devised to mark pluripotent stem cells
(46).
To investigate the activity of the modiﬁed reprog-
ramming vectors, 5  105 early passage (P3) OG2-
MEFs were electroporated with 500 ng of plasmids
containing the reprogramming vectors together with
50 ng of the SB100X transposase expression plasmid.
After electroporation, cells were plated into geltrex-coated
six-well plates and grown in the absence of VPA. Cellular
morphology began to change around day 3
post-transfection, and small pre-iPS colonies were visible
as early as day 6. Red ﬂuorescence could be observed
around day 10 post-transfection in pre-iPS colonies,
whereas GFP ﬂuorescence appeared 3–4 days later, as
was previously observed by Hotta et al. (46). iPS
colonies with ES cell-like morphology ubiquitously
expressed both mCherry and GFP (Figure 5).
Generation of human iPS cells by SB transposition
To test the potential of the SB transposon-based system
for iPS reprogramming in human cells, HFFs were
electroporated with the reprogramming vectors
(pT2-OSKM or pT2-OSKML or pT2-OSKM/EOS-
mCherry) as described earlier. The ﬁrst iPS-like colonies
appeared 3weeks after transfection, the ﬁrst clumps being
harvested 4weeks after transfection (Figure 6A). mCherry-
positive colonies generated with the OSKM/
EOS-mCherry construct (Figure 5) appeared as early as
day 6 (Figure 6A). The newly formed cells were morpho-
logically indistinguishable from ES colonies
(Figure 6B-D). As observed with the mouse cells, the
presence of Lin28 enhanced reprogramming: cells trans-
fected with pT2-OSKML yielded more colonies, and the
ﬁrst signs of reprogramming appeared 1–2 days earlier.
Furthermore, similar to mouse iPS cells, the majority of
human iPS cell clones contained multiple transposon in-
sertions in the range of 2–5 copies per cell (data not
shown).
miRNAs have been reported to promote somatic cell
reprogramming (29,53). To accelerate HFF reprog-
ramming, we employed an SB-based reprogramming
vector containing OSKM and the miRNA302/367
cluster (Figure 1B). ES-like colonies derived with this
vector were observed within 6–7 days after transfection,
1week earlier than with the OSKM vector, suggesting that
the expression of miRNA302/367 improved the temporal
kinetics of reprogramming (Figure 6A). The miRNA302/
367 cluster improved reprogramming efﬁciency up to
15-fold compared with OSKM alone (Figure 6E).
iPS cell colonies were examined for markers of
pluripotency. To investigate the DNA methylation status
of the endogenous Oct4 and Nanog promoters, bisulﬁte
sequencing on genomic DNA samples isolated from
human iPS cells and their parental HFF ﬁbroblasts was
performed. As shown in Figure 7A, the promoter regions
of Oct4 and Nanog were demethylated in human iPS cells
and methylated in HFF ﬁbroblasts, indicating that the
epigenetic state of the Oct4 and Nanog genes was success-
fully reprogrammed from a transcriptionally repressed to
an active state. Human iPS cells uniformly expressed the
pluripotency markers Oct4, Sox2, SSEA4, Tra-1-60,
Tra-1-81 and AP as determined by immunocytochemistry,
whereas the parental HFF cells were negative for these
markers (Figure 7B). In addition, cells presented de novo
expression of Nanog (Supplementary Figure S2A).
Further analyses by confocal microscopy and by ﬂow
cytometry conﬁrmed that iPS cells were positive for
SSEA4 and podocalyxin (Supplementary Figure S2B–E).
Human iPS cells and HFFs showed differential expression
of CD44 and CD73 markers that are characteristic to
more differentiated cellular phenotypes, and thus a
decrease in their expression in iPS cells was expected and
observed (Supplementary Figure S3). In addition, human
iPS cell lines analyzed by quantitative RT-PCR
(qRT-PCR) showed similar expression proﬁles of en-
dogenous pluripotency genes compared with HES-3
(Figure 7C). Global transcriptome analyses further con-
ﬁrmed the induction of 26 important pluripotency-
associated factors (Supplementary Figure S4). The
dendogram (Figure 7D) and principal component
analysis (Figure 7E) of these data sets showed that all
human iPS cell lines clustered together, but were slightly
different from a control data set of human ES cells
(HuES6), consistent with earlier ﬁndings indicating that
ES and iPS cells have similar, but not identical transcrip-
tion proﬁles (54). Finally, karyotype analysis was done on
one selected human iPS cell clone; these cells retained a
Figure 3. Continued
probe are plotted against the chromosomal localization from 1pter to y. Values around the baseline mean normal copy number state (2 n), values
above 0.5 mean a gain (3 n or >), values below 0.5 mean mono-allelic loss (1 n) and values below 3 mean bi-allelic loss. Copy number states are
shown along each chromosome in more detail. The apparent loss of X chromosome is due to sex-mismatch hybridization. (E) DNA methylation of
the Nanog promoter region analyzed by bisulﬁte sequencing. Open and closed circles indicate unmethylated and methylated CpG dinucleotides,
respectively. (F) qRT-PCR analyses of mouse ES cell-speciﬁc genes in parental and exchanged, reprogramming factor-free mouse iPS cells.
Expression levels of mouse ES cell-speciﬁc genes were normalized to Gapdh, and compared with levels in OG2 cells.
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Figure 4. In vitro differentiation of exchanged mouse iPS cells into lineages from all three germ layers. (A) Immunostaining for a-SMA (mesoderm),
b3-Tubulin (ectoderm) and Sox17 (endoderm) is shown. Oct4-GFP expression declines in EBs derived from exchanged iPS cells. (B) Multi-lineage
differentiation of exchanged, reprogramming factor-free mouse iPS cells was determined by qPCR for markers of the three germ layer markers.
Data are normalized to Gapdh, and relative to undifferentiated mouse iPS cells.
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normal karyotype, irrespective of passage number
(Figure 7F). Karyotyping by COBRA-FISH analysis on
two additional clones indicated that >65% of the cells had
a normal karyotype indistinguishable from that of the
parental HFF cells (Supplementary Figure S5).
To investigate the transcriptional status of the
reprogramming transgene construct in human iPS cells,
expression of transgenes and endogenous pluripotency
genes was determined by qRT-PCR (Supplementary
Figure S6A). As previously seen with viral vector-derived
human iPS cell lines, which sustain a low but detectable
residual transgene expression (55,56), the SB-derived
human iPS cells showed low expression of the
reprogramming transgenes. In contrast, expression of en-
dogenous Oct4 and Sox2 was consistently upregulated
relative to the parental HFF cells. Unlike in mouse iPS
cells, the mCherry signal was lost in human ES-like
colonies after 3 weeks in culture, consistent with transgene
silencing that was reversible by treating the cells with
5-Aza-20-Deoxycytidine (5-Aza) (Supplementary Figure
S6B).
Human iPS cells obtained by SB transposon-based
reprogramming were subjected to in vitro differentiation
studies by allowing them to form EBs (Figure 8A), which
were assessed for expression of markers of the three germ
layers. EBs were positive for alpha-fetoprotein (AFP)
(endoderm), alpha-smooth muscle actin (a-SMA)
(mesoderm) and betaIII-tubulin (ectoderm) as determined
by immunocytochemistry (Figure 8B). Human iPS cell
clones were subjected to gene expression (mRNA)
analysis, and found to display upregulated expression of
multiple, speciﬁc differentiation markers representing the
three germ layers (Figure 8C). Expression of Oct4 and
Nanog decreased, and expression of Pax6 increased
(probably in parallel with the appearance of neuron-like
cells) during differentiation, whereas HFFs were negative
for these markers (Supplementary Figure S7). Expression
of CAPG, a marker characteristic to skin cells, showed
high initial expression in HFFs, and its expression
declined in iPS or differentiated cells (Supplementary
Figure S7).
In addition to expression of markers of germ layers,
EBs can be used to demonstrate the differentiation poten-
tial of pluripotent stem cells by histological evidence of
tissue-like structures that resemble early embryonic devel-
opment (48). Thus, to further demonstrate functional
pluripotency and differentiation potential of human iPS
cells, we performed histological analysis of 20-day-old
EBs. Hematoxylin- and eosin-stained EB sections were
examined for morphological evidence of tissue differenti-
ation. As shown in Figure 8D, tri-lineage differentiation
was evidenced by the presence of neural rosettes
(ectoderm), muscle ﬁber (mesoderm) and gut epithelium
(endoderm) tissue-like structures characteristic for each of
the three germ layers. Taken together, these data demon-
strate that SB-derived human iPS cells were
Figure 5. Generation of mouse and human iPS cells by SB transposon-based, pluripotency-reporting reprogramming vectors. Mouse and human iPS
colonies were generated from OG2 MEFs and from HFFs, respectively. The resulting iPS cells express GFP from the Oct4 promoter and mCherry
from the EOS(3+) promoter. Human iPS cells express mCherry from the EOS(3+) promoter. A timeline of mouse iPS cell generation with the
SB-based pluripotency reprogramming vector is shown. OG2 cells were electroporated with pT2-OSKML/EOS-mCherry and the SB100X
transposase, and grown in mouse iPS medium in the absence of VPA. Cellular morphology began to change around day 3 post-transfection, and
small pre-iPS colonies were visible as early as day 6. Around day 10 post-transfection pre-iPS colonies started to express the mCherry signal, while
GFP ﬂuorescence appeared several days later, around day 14. iPS clones with typical ES-like morphology and expressing both RFP and GFP
ﬂuorescence could be picked from day 18.
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reprogrammed to pluripotency, and closely recapitulated
the functional properties of human ES cells.
DISCUSSION
The advantage of SB transposon-based gene delivery is
that it combines the favorable features of viral vectors
with those of naked DNA molecules. Namely, owing to
permanent genomic insertion of transgene constructs
(Figure 1A), transposition-mediated gene delivery can
lead to sustained and efﬁcient transgene expression both
in vitro (37,57) and in preclinical animal models (58). The
recent development of the SB100X hyperactive
transposase (37) allows efﬁcient stable gene transfer fol-
lowing non-viral gene delivery into therapeutically
relevant primary cell types, including stem or progenitor
cells. For example, the use of the SB100X system yielded
robust gene transfer efﬁciencies into human hematopoietic
progenitors (37,57), mesenchymal stem cells, muscle stem/
progenitor cells (myoblasts), iPS cells (59) and T cells (60).
These cells are relevant targets for stem cell biology and
for regenerative medicine and gene- and cell-based
therapies of complex genetic diseases.
Here, we demonstrated the applicability of the SB trans-
poson system for the efﬁcient generation of iPS cells from
both mouse and human ﬁbroblasts. The efﬁciency of iPS
cell derivation with SB transposon vectors approaches
that obtained with MLV-derived retroviral vectors ex-
pressing each of the four factors separately (0.1% in
MEFs and 0.01% in human ﬁbroblasts) [reviewed in
(4)]. The OSKML vectors were more efﬁcient in iPS
reprogramming than the OSKM vectors (Figure 2A).
It was demonstrated earlier that ectopic expression of
Lin28 can accelerate iPS cell formation that is directly
proportional to the cell division rate [reviewed in (3)].
This effect of Lin28 on increased cell proliferation could
amplify the number of target cells, in which each daughter
cell has an independent probability of becoming an iPS
cell, while the elevated rates of DNA replication may be a
necessary prerequisite for epigenetic changes such as DNA
and histone modiﬁcations to occur and allow the transi-
tion to pluripotency [reviewed in (3)]. In addition, it was
suggested recently by Wang and coworkers that transcrip-
tional reactivation of Oct4 target genes might be a
rate-limiting step in the conversion of somatic cells to
pluripotent cells (61). Since it is known that Lin28 facili-
tates the expression of Oct4 in human ES cells at the
post-transcriptional level (62), it is possible that elevated
levels of Oct4 induce faster activation of Oct4 targets,
thereby facilitating the reprogramming process.
Figure 6. Generation of human iPS cells with the SB reprogramming transposon system. (A) Timeline of SB-mediated iPS reprogramming. HFFs
were electroporated with an SB transposon containing the reprogramming factors and the SB100X transposase. After electroporation, cells were
seeded to one geltrex-coated well of a six-well plate. Cellular morphology began to change from day 4 post-transfection, and small colonies were
formed as early as day 6. When the pluripotency-reporting transposon vector was used, mCherry-positive ES-like colonies formed 2 weeks
post-transfection, allowing real-time monitoring of the formation of human iPS cells. The miRNA302/367 promoted apparence of small colonies
and ES-like colonies at 2 days and 1 week post-electroporation, respectively, earlier than OSKM. iPS colonies were picked after 3 weeks.
(B) Conﬂuent HFF cells grow in monolayers showing a typical ﬁbroblast morphology. (C) Three to four weeks after transfection with transposons
containing the reprogramming cassettes colonies were formed, which were picked and expanded. (D) Morphology of established human iPS cell line
shows ES and iPS cell-like characteristics when grown on feeder cells. (E) iPS colony forming efﬁciencies of reprogramming vectors. Colonies were
stained with AP and counted 3 weeks after transfection.
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It was reported earlier that the addition of VPA to the
cells during reprogramming enhanced the reprogramming
efﬁciency of mouse and human ﬁbroblasts (23,50).
However, this effect was observed neither in earlier
studies with PB reprogramming vectors (35) nor here
with SB vectors. Namely, we observed an increase in
reprogramming efﬁciency and kinetics in the absence of
VPA. However, even though the iPS cell colonies
generated in the absence of VPA were AP-positive, they
did not express Oct4 promoter-driven GFP ubiquitously,
and had a characteristically different cellular morphology.
Yusa et al. observed a dramatic growth suppression of the
un-reprogrammed colonies by VPA, noting that even
though the partially reprogrammed colonies contained
Nanog-positive patches or subcolonies where
reprogramming apparently did occur, the surrounding
un-reprogrammed cells prevented reprogrammed cells
from expanding and forming ES cell-like colonies (35).
Therefore, passaging and trypsinization could act to
‘free’ such reprogrammed subcolonies from un-
reprogrammed neighbor cells, and facilitate their further
growth, as observed here.
In this study, we also created SB-based pluripotency-
reporting reprogramming vectors by incorporating an
EOS(3+) promoter-enhancer sequence-driven mCherry
ﬂuorescence marker in the OSKM and OSKML
reprogramming vectors. This pluripotency-reporting
cassette was more sensitive than the endogenous Oct4-
GFP reporter cassette: iPS cells emitted red ﬂuorescence
at an earlier time point and with higher expression
than the Oct4-GFP cassette, as was previously
reported by Hotta et al. (46). The sensitivity and the
high expression of the pluripotency marker gene makes
these reprogramming vectors very useful for detecting
reprogrammed patches or subcolonies of partially
reprogrammed clones in cultures obtained with low
amounts of reprogramming vectors, or in cells that are
difﬁcult to reprogram, which could then be picked
and passaged to obtain completely reprogrammed
colonies.
Figure 7. Characterization of human iPS cells. (A) DNA methylation of the promoter regions of the Oct4 and Nanog genes analyzed by bisulﬁte
sequencing. Open and closed circles indicate unmethylated and methylated CpG dinucleotides, respectively. (B) Immunostaining for Oct4, Sox2,
SSEA4, Tra-1-60 and Tra-1-81 in human iPS cells as well as AP staining show expression of pluripotency markers. (C) Heat map showing similar
expression proﬁles of pluripotency genes in human iPS cells and the human ES cell line HES-3, as determined by qRT-PCR. Data were normalized
against Gapdh, and relative to HFF. (D) Dendogram and (E) principal component analysis depicting the transcriptome proﬁles of the human iPS cell
lines 1–7, 2–3, 5 and 6 in comparison to a set of human ES cells (HuES6) and parental ﬁbroblasts (HFF). (F) Karyotype analysis of human iPS cells.
Human iPS cells of clone C5 retained normal karyotypes after 55 passages.
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Figure 8. EB-mediated differentiation of human iPS cells. (A) iPS cells were kept in suspension on polyHEMA-coated six-well plates in EB medium
to allow formation of cystic EBs for 6 days. (B) After 6 days, EBs were placed onto gelatin-coated plates, and the spontaneously differentiating,
attached cells were assessed for markers of the three germ layers. Cells were positive for the endodermal marker AFP, the mesodermal marker
a-SMA and the ectodermal marker bIII-tubulin. (C) Multi-lineage differentiation of human iPS cells was determined by qPCR for markers of the
three germ layer markers, and compared with undifferentiated human iPS cells. Data are normalized to Gapdh, and relative to undifferentiated
human iPS cells. (D) Histological evidence of EB germ layer differentiation. Shown are images of hematoxylin- and eosin-stained histological sections
of EBs obtained from human iPS cells. Tri-lineage differentiation potential is evidenced by the presence of structures characteristic to ectodermal
(neural rosettes, left), mesodermal (muscle ﬁber, middle) and endodermal (gut epithelium, right) tissues, indicated by arrows.
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We demonstrated that the efﬁciency of reprogramming
can be increased by increasing the amounts of the trans-
poson reprogramming vectors electroporated into the
cells. This suggests that it might be possible to further
improve the efﬁciency of SB-mediated reprogramming
by further increasing the amounts of the electroporated
reprogramming vectors. However, in light of our
analysis of transposon copy numbers in iPS colonies,
such a strategy may prove counter-productive. Namely,
transposon copy number analysis in the iPS clones
revealed that even at reduced transposon vector doses
the majority of iPS clones contained multiple (at least 2)
transposon insertions. As earlier studies have shown that
it is relatively straightforward to generate single-copy in-
sertions in HeLa cells by titrating the transposon compo-
nents in the transfection reactions (37,38), these results
suggest selection for >1 copies during iPS cell
reprogramming, which might be limited by the levels of
expression of the reprogramming factors. Two papers
have demonstrated that the quick reactivation of the en-
dogenous Oct4 gene is a crucial step in the reprogramming
process (29,61), and that the fusion of Oct4, Sox2 and
Nanog to the transcriptional transactivation domain of
herpes simplex virus protein VP16 can dramatically
increase reprogramming speed and efﬁciency (61). This
discovery indicates that by improving the efﬁciency of
the reprogramming vectors by using such high-
performance engineered factors or by increasing reprog-
ramming factor expression by codon optimization and
additional elements incorporated in the transgene
cassette design (63), it might be possible to generate
single-copy iPS cell clones more efﬁciently.
It has been shown previously that miRNAs are essential
regulators of cell fate and pluripotency and play import-
ant role in somatic cell reprogramming (53,64–67). Recent
studies have demonstrated that the miRNA cluster 302/
367 promotes generation of human iPS cells (53), and can
drive efﬁcient somatic cell reprogramming even in the
absence of the exogenous reprogramming factors (29). In
agreement with those ﬁndings, addition of the miRNA
cluster 302/367 to our pT2-OSKM reprogramming
vector resulted in 15-fold improvement in the efﬁciency
of human iPS cell generation. However, in the mouse
system we did not observe a similar positive effect on
the generation of iPS cells. In addition, the morphology
of mouse iPS colonies generated with the pT2-OSKM-
miR-302/367 vector resembled that of epiblast stem cells
(EpiSCs) (68–70), and was distinct from the morphology
of the ES cell-like iPS clones generated with pT2-OSKM
and pT2-OSKML vectors (Supplementary Figure S8).
This observation could be explained in light of miRNA
expression proﬁles in both ES- and EpiSCs indicating that
those two pluripotent states have distinct miRNA signa-
tures (71). According to the latest reports, a ‘na¿ve’ pluri-
potent state compatible with the inner cell mass and early
epiblast is represented by murine ES cells that predomin-
antly express the miR-290/295 cluster, whereas a ‘primed’
pluripotent state, similar to the post-implantation epiblast
and represented by murine EpiSCs and human ES cells,
predominantly expresses the miR-302/376 cluster (64,71).
In this manner, use of the pT2-OSKM-miR-302/376
vector in our reprogramming experiments could have
shifted the balance in the mouse system from generation
of the typical iPS colonies with an ES cell-like morphology
toward the derivation of cells resembling EpiSCs, which
are characterized by the high expression of miR-302/362
cluster (71).
A major goal of human cell-based therapy is to develop
methods that allow treatment of patients afﬂicted with
genetic and degenerative disorders with a ready supply
of deﬁned transplantable cells. Because of their plasticity
and unlimited capacity for self-renewal, human iPS cells
have been proposed for use in ‘personalized’ cell-based
therapies. Targeted genetic manipulation of stem cells is
well advanced, and offers the opportunity to correct
monogenic, life-threatening genetic defects. For such
purposes it would be necessary to deliver and stably inte-
grate a therapeutic gene construct into the genomes of
autologous, patient-derived iPS cells, followed by differ-
entiation into a linage of interest and transplantation of
genetically corrected (‘healed’) cells. Such protocols will be
especially justiﬁed in conditions, where autologous,
patient-derived target cells are scarce and/or not
amenable to genetic correction by ex vivo technologies.
For example, Fanconi anemia (FA) patients with an
advanced bone marrow failure have almost no hematopoi-
etic stem cells (HSCs) in their hematopoietic tissues,
precluding a classic HSC-based ex vivo gene therapy.
In a gene therapy setup, an SB transposon vector could
carry both a reprogramming cassette ﬂanked by
homospeciﬁc loxP sites and a therapeutic cassette. After
reprogramming has taken place, the reprogramming
cassette could be excised by Cre recombinase-mediated
excision. In another scenario, the SB transposon could
deliver the reprogramming cassette ﬂanked by heter-
ospeciﬁc loxP sites. Following generation of iPS cells,
the reprogramming cassette could be exchanged via Cre
recombinase-mediated exchange with a therapeutic gene
construct that is also ﬂanked by the same recombination
sites. We demonstrated the applicability of the latter
strategy by site-directed integration of a ﬂuorescent
marker into a transposon-tagged locus (Figure 3). This
strategy would allow phenotype correction and reprogr-
amming in a single step. This would be especially import-
ant in FA, because it has been previously shown that
phenotype correction is required for iPS reprogramming
in FA ﬁbroblasts (5). For a therapeutic application, it will
be important that the therapeutic transgene cassette is
inserted into a ‘safe harbor’ locus to avoid genotoxic
effects and unwanted phenotypes. From the currently
applied integrating vector systems, the SB transposon is
especially noteworthy for its lack of preference for insert-
ing into genes (39). The reprogramming SB transposon
was integrated into a TA site on chromosome X in the
mouse iPS cells that were subsequently used for RMCE
(Supplementary Figure S9). Importantly, there are no
known protein coding and miRNA genes in a window
of ±20 kb around the transposon insertion site. This
provides proof-of-concept for the generation of iPS cells
with a single SB transposon integrated into a ‘safe harbor’
chromosomal locus. The establishment of safe protocols
for the generation and clonal tracking of iPS cells by
1844 Nucleic Acids Research, 2013, Vol. 41, No. 3
rational genome engineering along with advanced differ-
entiation protocols of iPS cells would open the ﬁeld for
potential correction of a multitude of severe monogenetic
or acquired disorders of hematopoiesis, including aplastic
anemias, immunodeﬁciencies, storage disorders, infecious
diseases such as HIV infection and certain forms of
cancer.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1–9 and Supplementary Methods.
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